These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38441243)

  • 21. Assessment of endpoints for clinical trials for localized prostate cancer.
    Schellhammer P; Cockett A; Boccon-Gibod L; Gospodarowicz M; Krongrad A; Thompson IM; Scardino P; Soloway M; Adolfsson J
    Urology; 1997 Apr; 49(4A Suppl):27-38. PubMed ID: 9111612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MUK
    Brown S; Sherratt D; Hinsley S; Flanagan L; Roberts S; Walker K; Hall A; Pratt G; Messiou C; Jenner M; Kaiser M;
    BMJ Open; 2021 Mar; 11(3):e046225. PubMed ID: 33762245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.
    Landgren O; Kyle RA; Rajkumar SV
    Clin Cancer Res; 2011 Mar; 17(6):1243-52. PubMed ID: 21411440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
    Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
    Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telehealth exercise to Improve Physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial.
    Lee K; Nathwani N; Shamunee J; Lindenfeld L; Wong FL; Krishnan A; Armenian S
    Trials; 2022 Nov; 23(1):921. PubMed ID: 36329525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fundamentals in the management of multiple myeloma.
    Fadilah SA
    Med J Malaysia; 2010 Sep; 65(3):231-9. PubMed ID: 21939177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials.
    Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2004 Feb; 29(1):85-94. PubMed ID: 14748903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple myeloma: Current and future management in the aging population.
    Fotiou D; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA
    Maturitas; 2020 Aug; 138():8-13. PubMed ID: 32631590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.
    Lonial S; Rajkumar SV; Mateos MV
    Lancet Haematol; 2022 Feb; 9(2):e162-e165. PubMed ID: 35114153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Al-Kadhimi Z; Costa LJ; Hahn T; Hari P; Hillengass J; Jacob A; Munshi NC; Oliva S; Pasquini MC; Shi Q; Stadtmauer EA; Waldvogel SL; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e7-e15. PubMed ID: 31526843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple myeloma precursor disease.
    Landgren O; Waxman AJ
    JAMA; 2010 Dec; 304(21):2397-404. PubMed ID: 21119086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Holstein SA; Suman VJ; McCarthy PL
    Curr Hematol Malig Rep; 2019 Feb; 14(1):31-38. PubMed ID: 30661162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refining endpoints in brain tumor clinical trials.
    Meyers CA; Rock EP; Fine HA
    J Neurooncol; 2012 Jun; 108(2):227-30. PubMed ID: 22451194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
    Methy N; Bedenne L; Bonnetain F
    BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and emerging treatments for multiple myeloma.
    Schwartz RN; Vozniak M
    J Manag Care Pharm; 2008 Sep; 14(7 Suppl):12-9. PubMed ID: 18774881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
    Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.